Cassava Sciences, Inc.

Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to

Are you a current or former employee of the company?*YesNo


+Additional Purchases


+Additional Sales

If you prefer, you may submit your transaction information or comments/questions in the box below:

There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.

We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at, or by email at

If you choose to take no action, you can remain an absent class member.

Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.

The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Portnoy Law Firm
Lesley F. Portnoy, Esq.,
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067

The complaint asserts that throughout the class period, the defendants provided materially inaccurate and deceptive statements about the company’s business practices, operational procedures, and adherence to regulatory guidelines. In detail, it is claimed that the defendants disseminated false or misleading information or neglected to reveal that:

  1. the company did not uphold sufficient and robust data management controls and protocols pertaining to its pharmaceutical research endeavors;
  2. consequently, the data disseminated to support simufilam was vulnerable to alterations that exaggerated the drug’s efficacy;
  3. as such, Cassava misrepresented the success of its research initiatives and the potential efficacy and market viability of simufilam;
  4. all these issues, upon being disclosed, were poised to inflict considerable financial and/or reputational damage on the company; and
  5. therefore, the company’s statements to the public were substantially false and misleading at all times of relevance.